title: Poor response to thiopurine in inflammatory bowel disease: how to overcome therapeutic resistance?
authors.affiliation: Assistance publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Biochimie, Pharmacogénétique et Oncologie Moléculaire, Paris, France.
authors.forename: Laurent
authors.initials: L
authors.lastname: Chouchana
authors.forename: Denis
authors.initials: D
authors.lastname: Roche
authors.forename: Raymond
authors.initials: R
authors.lastname: Jian
authors.forename: Philippe
authors.initials: P
authors.lastname: Beaune
authors.forename: Marie-Anne
authors.initials: MA
authors.lastname: Loriot
mesh_terms: D000068879:Adalimumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D001379:Azathioprine / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D003093:Colitis, Ulcerative / Q000188:drug therapy*; D004351:Drug Resistance; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D000069285:Infliximab; D015122:Mercaptopurine / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D012008:Recurrence; D017211:Treatment Failure; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D055815:Young Adult
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D015122:Mercaptopurine; D000068879:Adalimumab; D001379:Azathioprine